Novel Cell-Based Bioassays for Monoclonal Antibody and Bispecific Molecules in PD-1 Blockade Monotherapy and Combination Therapy

Part # PS428


We have developed a suite of MOA-based reporter bioassays designed for PD-1 blockade monotherapy as well as PD-1 in combination with a second immune checkpoint receptor. They overcome the limitations of primary cell-based assays and can be used for antibody screening, characterization, potency and stability studies. These bioassays provide the following:

  • Biologically relevant measurement of antibody MOA
  • Consistent and reliable thaw-and-use format
  • Easy implementation, rapid results

Printed in USA.